Zhejiang Hisoar Pharmaceutical Co Ltd Cash Flow-to-Debt Ratio
Zhejiang Hisoar Pharmaceutical Co Ltd cash flow-to-debt ratio. Zhejiang Hisoar Pharmaceutical Co Ltd (002099) has a Cash Flow-to-Debt Ratio of 0.01x as of September 2025, meaning its operating cash flow of CN¥15.48 Million could theoretically repay 0% of its total liabilities (CN¥2.17 Billion) in one year. Check cash flow reinvestment rate of Zhejiang Hisoar Pharmaceutical Co Ltd to assess the company's total reinvestment commitment from operating cash flow.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Cash Flow-to-Debt Ratio of Zhejiang Hisoar Pharmaceutical Co Ltd (2003–2024)
Cash flow-to-debt ratio of Zhejiang Hisoar Pharmaceutical Co Ltd from 2003 to 2024. Historical debt coverage capacity for Zhejiang Hisoar Pharmaceutical Co Ltd across 22 annual periods. Check 002099 cash flow quality index to evaluate the quality of earnings relative to operating cash generation.
Zhejiang Hisoar Pharmaceutical Co Ltd Cash Flow-to-Debt Ratio by Year (2003–2024)
Zhejiang Hisoar Pharmaceutical Co Ltd cash flow-to-debt ratio by year from 2003 to 2024. Year-by-year debt coverage analysis for Zhejiang Hisoar Pharmaceutical Co Ltd. For the full cash flow conversion analysis, see how efficiently does Zhejiang Hisoar Pharmaceutical Co Ltd generate cash.
| Year | CF-to-Debt Ratio | Operating CF (CNY) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2024 | 0.08x | CN¥174.83 Million | CN¥2.32 Billion | ▼ -40.0% |
| 2023 | 0.13x | CN¥240.54 Million | CN¥1.92 Billion | ▲ +147.1% |
| 2022 | 0.05x | CN¥116.09 Million | CN¥2.29 Billion | ▼ -5.5% |
| 2021 | 0.05x | CN¥102.36 Million | CN¥1.91 Billion | ▼ -86.7% |
| 2020 | 0.40x | CN¥533.87 Million | CN¥1.33 Billion | ▼ -32.8% |
| 2019 | 0.60x | CN¥612.40 Million | CN¥1.02 Billion | ▲ +24.4% |
| 2018 | 0.48x | CN¥791.45 Million | CN¥1.64 Billion | ▲ +989.5% |
| 2017 | 0.04x | CN¥102.68 Million | CN¥2.32 Billion | ▼ -85.0% |
| 2016 | 0.29x | CN¥629.42 Million | CN¥2.14 Billion | ▼ -19.8% |
| 2015 | 0.37x | CN¥462.16 Million | CN¥1.26 Billion | ▲ +89.6% |
| 2014 | 0.19x | CN¥191.56 Million | CN¥988.73 Million | ▲ +370.2% |
| 2013 | 0.04x | CN¥60.85 Million | CN¥1.48 Billion | ▼ -73.1% |
| 2012 | 0.15x | CN¥180.73 Million | CN¥1.18 Billion | ▲ +15.5% |
| 2011 | 0.13x | CN¥92.62 Million | CN¥698.17 Million | ▼ -63.2% |
| 2010 | 0.36x | CN¥180.88 Million | CN¥502.28 Million | ▲ +59.0% |
| 2009 | 0.23x | CN¥98.38 Million | CN¥434.48 Million | ▲ +244.4% |
| 2008 | 0.07x | CN¥30.61 Million | CN¥465.58 Million | ▼ -47.1% |
| 2007 | 0.12x | CN¥51.14 Million | CN¥411.69 Million | ▼ -19.2% |
| 2006 | 0.15x | CN¥61.88 Million | CN¥402.66 Million | ▲ +67.8% |
| 2005 | 0.09x | CN¥36.07 Million | CN¥393.76 Million | ▼ -44.8% |
| 2004 | 0.17x | CN¥42.36 Million | CN¥255.35 Million | ▲ +943.5% |
| 2003 | -0.02x | CN¥-5.45 Million | CN¥277.36 Million | — |